DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 17-970/S-053

AstraZeneca Pharmaceuticals LP
1800 Concord Pike
P.O. Box 8355
Wilmington, DE 19803-8355

Attention: E. Jane Valas, Ph.D.
Associate Director, Regulatory Affairs

Dear Dr. Valas:

Please refer to your supplemental new drug application dated September 17, 2004, received September 20, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for NOLVADEX® (tamoxifen citrate) Tablets.

This supplemental new drug application provides for changes to the **PRECAUTIONS- Nursing Mothers** section of the package insert to correct the perceived inconsistency between the Prescribing Information and the Medication Guide with respect to nursing mothers.

We completed our review of this application, as amended. This application is approved, effective on the date of this letter, for use as recommended in the agreed-upon labeling text and with the minor editorial revision listed below.

> In the final printed labeling, you should correct the subheading under **Nursing Mothers** to read "**Reduction in Breast Cancer Incidence in High Risk Women and Women with DCIS**".

The final printed labeling (FPL) must be identical, and include the minor editorial revision indicated, to the submitted labeling (package insert and Medication Guide submitted September 17, 2004). This revision is a term of the approval of this application.

Please submit an electronic version of the FPL according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDA*. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available but no more than 30 days after it is printed. Individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, designate this submission "**FPL for approved supplement NDA 17-970/S-053**." Approval of this submission by FDA is not required before the labeling is used.

All applications for new active ingredients, new dosage forms, new indications, new routes of administration, and new dosing regimens are required to contain an assessment of the safety and effectiveness of the product in pediatric patients unless this requirement is waived or deferred. We are waiving the pediatric study requirement for this application.

We remind you of your postmarketing study commitments in your submission dated April 30, 1998 (S-040). These commitments are listed below.

Commitment #1

Thromboembolic events are a significant risk for women taking tamoxifen. As discussed at Oncologic Drugs Advisory Committee and recommended by the Committee, the applicant should perform a study to evaluate the etiology of drug-related clotting events, including assays for Factor V Leiden and activated protein C resistance. The study protocol should be submitted for review prior to initiation.

Commitment #2

All participants receiving tamoxifen in the NSABP P-1 trial who have consented to follow-up after the original 7-year treatment period will have long-term follow-up for the events of cancer (invasive breast, non-invasive breast, endometrial and other cancers) and death as specified in NSABP protocol P-1.EXT. Data should be submitted at least yearly until October 29, 2018, provided NSABP continues to be funded by the National Cancer Institute.

Commitment #4

Provide the results of the ongoing NSABP central pathology review, to include tumor grade as well as any other analyses you perform. These results can be provided on a rolling basis by category (for example, breast cancers, endometrial cancers, etc.). Provide the anticipated timetable for submission.

Submit clinical protocols to your IND for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all study final reports to this NDA. In addition, under 21 CFR 314.81(b)(2)(vii) and 314.81(b)(2)(viii), you should include a status summary of each commitment in your annual report to this NDA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies, number of patients entered into each study. All submissions, including supplements, relating to these postmarketing study commitments must be prominently labeled "**Postmarketing Study Commitment Protocol**", "**Postmarketing Study Commitment Final Report**", or "**Postmarketing Study Commitment Correspondence**."

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Christy Cottrell, Consumer Safety Officer, at (301) 594-5778.

Sincerely,

{See appended electronic signature page}

Richard Pazdur, M.D.
Director
Division of Oncology Drug Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosure

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

Richard Pazdur

3/17/05 12:43:39 PM